{"count": 10, "results": [{"_id": "36839925", "pmid": 36839925, "pmcid": "PMC9962408", "title": "Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders", "journal": "Pharmaceutics", "authors": ["Górniak A", "Czapor-Irzabek H", "Złocińska A", "Gawin-Mikołajewicz A", "Karolewicz B"], "date": "2023-02-10T00:00:00Z", "doi": "10.3390/pharmaceutics15020603", "meta_date_publication": "2023 Feb 10", "meta_volume": "15", "meta_issue": "2", "meta_pages": "", "score": 50270.38, "text_hl": "Screening of @CHEMICAL_Fenofibrate @CHEMICAL_MESH:D011345 @@@Fenofibrate@@@-@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@Lipid Disorders@@@", "citations": {"NLM": "Górniak A, Czapor-Irzabek H, Złocińska A, Gawin-Mikołajewicz A, Karolewicz B. Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders Pharmaceutics. 2023 Feb 10;15(2):. PMID: 36839925", "BibTeX": "@article{36839925, title={Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders}, author={Górniak A and Czapor-Irzabek H and Złocińska A and Gawin-Mikołajewicz A and Karolewicz B}, journal={Pharmaceutics}, volume={15}, number={2}}"}}, {"_id": "32410994", "pmid": 32410994, "pmcid": "PMC7201051", "title": "The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet", "journal": "Front Pharmacol", "authors": ["Zhang Q", "Fan X", "Ye R", "Hu Y", "Zheng T", "Shi R", "Cheng W", "Lv X", "Chen L", "Liang P"], "date": "2020-04-29T00:00:00Z", "doi": "10.3389/fphar.2020.00522", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "522", "score": 50254.957, "text_hl": "The Effect of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ on Gut Microbiota and @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@Lipid@@@ Metabolism in Hyperlipidemic @SPECIES_10116 @@@Rats@@@ Induced by a High-Fat Diet", "citations": {"NLM": "Zhang Q, Fan X, Ye R, Hu Y, Zheng T, Shi R, Cheng W, Lv X, Chen L, Liang P. The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet Front Pharmacol. 2020;11():522. PMID: 32410994", "BibTeX": "@article{32410994, title={The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet}, author={Zhang Q and Fan X and Ye R and Hu Y and Zheng T and Shi R and Cheng W and Lv X and Chen L and Liang P}, journal={Front Pharmacol}, volume={11}, pages={522}}"}}, {"_id": "19436666", "pmid": 19436666, "pmcid": "PMC2672455", "title": "Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin", "journal": "Vasc Health Risk Manag", "authors": ["Robinson JG"], "date": "2009-01-01T00:00:00Z", "doi": "10.2147/vhrm.s3190", "meta_date_publication": "2009", "meta_volume": "5", "meta_issue": "1", "meta_pages": "31-43", "score": 50092.156, "text_hl": "Management of complex @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@lipid abnormalities@@@ with a fixed dose combination of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and extended release niacin", "citations": {"NLM": "Robinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin Vasc Health Risk Manag. 2009;5(1):31-43. PMID: 19436666", "BibTeX": "@article{19436666, title={Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin}, author={Robinson JG}, journal={Vasc Health Risk Manag}, volume={5}, number={1}, pages={31-43}}"}}, {"_id": "23776861", "pmid": 23776861, "pmcid": "PMC3659875", "title": "The efficacy and safety of Simvastatin in the treatment of lipid abnormalities in diabetes mellitus", "journal": "Indian J Endocrinol Metab", "authors": ["Okeoghene OA", "Alfred A"], "date": "2013-01-01T00:00:00Z", "doi": "10.4103/2230-8210.107817", "meta_date_publication": "2013 Jan", "meta_volume": "17", "meta_issue": "1", "meta_pages": "105-9", "score": 50079.29, "text_hl": "The efficacy and safety of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ in the treatment of @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@lipid abnormalities@@@ in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@", "citations": {"NLM": "Okeoghene OA, Alfred A. The efficacy and safety of Simvastatin in the treatment of lipid abnormalities in diabetes mellitus Indian J Endocrinol Metab. 2013 Jan;17(1):105-9. PMID: 23776861", "BibTeX": "@article{23776861, title={The efficacy and safety of Simvastatin in the treatment of lipid abnormalities in diabetes mellitus}, author={Okeoghene OA and Alfred A}, journal={Indian J Endocrinol Metab}, volume={17}, number={1}, pages={105-9}}"}}, {"_id": "19018682", "pmid": 19018682, "title": "Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.", "journal": "Expert Rev Cardiovasc Ther", "authors": ["Vo AN", "Kashyap ML"], "date": "2008-11-01T00:00:00Z", "doi": "10.1586/14779072.6.10.1303", "meta_date_publication": "2008 Nov", "meta_volume": "6", "meta_issue": "10", "meta_pages": "1303-10", "score": 50075.02, "text_hl": "Fixed-dose combination of extended-release @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@ plus @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ for @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@lipid disorders@@@.", "citations": {"NLM": "Vo AN, Kashyap ML. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1303-10. PMID: 19018682", "BibTeX": "@article{19018682, title={Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.}, author={Vo AN and Kashyap ML}, journal={Expert Rev Cardiovasc Ther}, volume={6}, number={10}, pages={1303-10}}"}}, {"_id": "9566646", "pmid": 9566646, "title": "Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia.", "journal": "J Intern Med", "authors": ["Nordøy A", "Bønaa KH", "Nilsen H", "Berge RK", "Hansen JB", "Ingebretsen OC"], "date": "1998-02-01T00:00:00Z", "doi": "10.1046/j.1365-2796.1998.00297.x", "meta_date_publication": "1998 Feb", "meta_volume": "243", "meta_issue": "2", "meta_pages": "163-70", "score": 50051.645, "text_hl": "The purpose of this study was to evaluate the efficiency and the safety of treatment with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ and @CHEMICAL_Fatty_Acids_Omega_3 @CHEMICAL_MESH:D015525 @@@omega-3 fatty acids@@@ in @SPECIES_9606 @@@patients@@@ with this @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@lipid disorder@@@. ", "citations": {"NLM": "Nordøy A, Bønaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 1998 Feb;243(2):163-70. PMID: 9566646", "BibTeX": "@article{9566646, title={Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia.}, author={Nordøy A and Bønaa KH and Nilsen H and Berge RK and Hansen JB and Ingebretsen OC}, journal={J Intern Med}, volume={243}, number={2}, pages={163-70}}"}}, {"_id": "15123521", "pmid": 15123521, "title": "HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.", "journal": "Circulation", "authors": ["Merx MW", "Liehn EA", "Janssens U", "Lütticken R", "Schrader J", "Hanrath P", "Weber C"], "date": "2004-06-01T00:00:00Z", "doi": "10.1161/01.CIR.0000129774.09737.5B", "meta_date_publication": "2004 Jun 1", "meta_volume": "109", "meta_issue": "21", "meta_pages": "2560-5", "score": 50050.48, "text_hl": "CONCLUSIONS: @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@, which is well established in the treatment of @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@lipid disorders@@@ and @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@coronary artery disease@@@, might have the additional potential of being an effective agent in @DISEASE_Sepsis @DISEASE_MESH:D018805 @@@sepsis@@@ treatment.", "citations": {"NLM": "Merx MW, Liehn EA, Janssens U, Lütticken R, Schrader J, Hanrath P, Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004 Jun 1;109(21):2560-5. PMID: 15123521", "BibTeX": "@article{15123521, title={HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.}, author={Merx MW and Liehn EA and Janssens U and Lütticken R and Schrader J and Hanrath P and Weber C}, journal={Circulation}, volume={109}, number={21}, pages={2560-5}}"}}, {"_id": "31676775", "pmid": 31676775, "pmcid": "PMC6825130", "title": "Characterizing the Role of HMG-CoA Reductase in Aryl Hydrocarbon Receptor-Mediated Liver Injury in C57BL/6 Mice", "journal": "Sci Rep", "authors": ["Dornbos P", "Jurgelewicz A", "Fader KA", "Williams K", "Zacharewski TR", "LaPres JJ"], "date": "2019-11-01T00:00:00Z", "doi": "10.1038/s41598-019-52001-2", "meta_date_publication": "2019 Nov 1", "meta_volume": "9", "meta_issue": "1", "meta_pages": "15828", "score": 50044.594, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ exposure decreased @CHEMICAL_Polychlorinated_Dibenzodioxins @CHEMICAL_MESH:D000072317 @@@TCDD@@@-induced @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@hepatic lipid accumulation@@@ in both sexes, but was most prominent in females. ", "citations": {"NLM": "Dornbos P, Jurgelewicz A, Fader KA, Williams K, Zacharewski TR, LaPres JJ. Characterizing the Role of HMG-CoA Reductase in Aryl Hydrocarbon Receptor-Mediated Liver Injury in C57BL/6 Mice Sci Rep. 2019 Nov 1;9(1):15828. PMID: 31676775", "BibTeX": "@article{31676775, title={Characterizing the Role of HMG-CoA Reductase in Aryl Hydrocarbon Receptor-Mediated Liver Injury in C57BL/6 Mice}, author={Dornbos P and Jurgelewicz A and Fader KA and Williams K and Zacharewski TR and LaPres JJ}, journal={Sci Rep}, volume={9}, number={1}, pages={15828}}"}}, {"_id": "27151383", "pmid": 27151383, "title": "Agaricus brasiliensis (sun mushroom) affects the expression of genes related to cholesterol homeostasis.", "journal": "Eur J Nutr", "authors": ["de Miranda AM", "Rossoni Júnior JV", "Souza E Silva L", "Dos Santos RC", "Silva ME", "Pedrosa ML"], "date": "2017-06-01T00:00:00Z", "doi": "10.1007/s00394-016-1217-x", "meta_date_publication": "2017 Jun", "meta_volume": "56", "meta_issue": "4", "meta_pages": "1707-1717", "score": 50043.473, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ was used as a positive control, as it is a typical drug prescribed for @<m>DISEASE_Pneumonia_Lipid</m> @DISEASE_MESH:D011017 @@@lipid disorders@@@. ", "citations": {"NLM": "de Miranda AM, Rossoni Júnior JV, Souza E Silva L, Dos Santos RC, Silva ME, Pedrosa ML. Agaricus brasiliensis (sun mushroom) affects the expression of genes related to cholesterol homeostasis. Eur J Nutr. 2017 Jun;56(4):1707-1717. PMID: 27151383", "BibTeX": "@article{27151383, title={Agaricus brasiliensis (sun mushroom) affects the expression of genes related to cholesterol homeostasis.}, author={de Miranda AM and Rossoni Júnior JV and Souza E Silva L and Dos Santos RC and Silva ME and Pedrosa ML}, journal={Eur J Nutr}, volume={56}, number={4}, pages={1707-1717}}"}}, {"_id": "19891279", "pmid": 19891279, "title": "Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.", "journal": "J Manag Care Pharm", "authors": ["Cziraky MJ", "Watson KE", "Talbert RL"], "date": "2008-10-01T00:00:00Z", "meta_date_publication": "2008 Oct", "meta_volume": "14", "meta_issue": "8 Suppl", "meta_pages": "S3-28; quiz S30-1", "score": 50030.6, "text_hl": "Finally, these modeling studies estimated that a fixed-dose niacin ER/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ combination therapy would reduce direct medical costs of @DISEASE_Coronary_Disease @DISEASE_MESH:D003327 @@@CHD@@@ events more effectively than would high-dose @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ monotherapy. ", "citations": {"NLM": "Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. PMID: 19891279", "BibTeX": "@article{19891279, title={Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.}, author={Cziraky MJ and Watson KE and Talbert RL}, journal={J Manag Care Pharm}, volume={14}, number={8 Suppl}, pages={S3-28; quiz S30-1}}"}}]}